Abstract
Psoriatic arthritis is an inflammatory arthritis, which occurs in up to 30% of individuals with psoriasis. Dermatologists and other physicians treating psoriasis are in an ideal position to screen for the condition, and with rheumatologists, strategize optimal therapy. Mild skin and joint manifestations may be treated effectively with topical agents, ultraviolet light therapy, and nonsteroidal anti-inflammatory drugs. More severe manifestations of the disease, including progressive peripheral joint damage, spine disease, enthesitis, dactylitis, and severe skin changes, require systemic therapy. Traditional systemic agents include methotrexate, sulfasalazine, and cyclosporine. When these agents are not adequate or not tolerated, new biologic agents, particularly antitumor necrosis factor (TNF) compounds, have shown significant and enduring benefit in all disease domains, improvement in quality of life and function, and inhibition of progressive joint damage.
Similar content being viewed by others
References and Recommended Reading
Husted JA, Gladman DD, Farewell VT, Cook RJ: Healthrelated quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45:151–158.
Wong K, Gladman DD, Husted J, et al.: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. Causes and risk of death. Arthritis Rheum 1997, 40:1868–1872.
Moll J, Wright V: Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55–78.
Helliwell P, Taylor W: Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005, 64(Suppl_2):ii3-ii8.
Taylor W, Marchesoni A, Arreghini M, et al.: A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 2004, 34:575–584.
Taylor W: ClASsification criteria for Psoriatic ARthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665–2673. Key paper describing the results of the CASPAR study, which establishes an updated classification criteria for PsA.
Leonard DG, O’Duffy JD, Rogers RS: Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978, 53:511–518.
Shbeeb M, Uramoto KM, Gibson LE, et al.: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000, 27:1247–1250.
Salonen S: The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations. Poster presented at the Spring Symposium of the European Academy of Dermatology and Venereology. Malta; February 2003.
Gelfand JM, Gladman DD, Mease PJ, et al.: Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53:573.
Offidani A, Cellini A, Valeri G, Giovagnoni A: Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray.ndings. Acta Derm Venereol 1998, 78:463–465.
Baeten D, Kruithof E, De Rycke L, et al.: Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005, 7:R359-R369.
De RyckeL, Vandooren B, Kruithof E, et al.: Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005, 52:2146–2158.
Veale D, Ritchlin C, FitzGerald O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005, 65(Suppl 2):ii26-ii29.
Kruithof E, Baeten D, De Rycke L, et al.: Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569-R580. Establishes the close relationship of the subsets of the spondyloarthropathies, especially AS and PsA, at a synovial cellular and immunohistochemical level, and their distinction from RA.
Krueger J, Bowcock A Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005, 64(Suppl 2):ii30-ii36. Comprehensive review of psoriasis pathophysiology.
Mease P, Goffe BS: Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005, 52:1–19. Comprehensive review of PsA: diagnosis, pathophysiology, assessment, and management.
Fransen J, Antoni C, Mease P, et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized, controlled trials of two TNF inhibitors. Ann Rheum Dis 2006, In press.
Husted JA, Gladman DD, Cook RJ, Farewell VT: Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998, 25:2146–2155.
Husted JA, Gladman DD, Farewell VT, et al.: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24:511–517.
Singh A, Mease P, Yu E, et al.: Health Assessment Questionnaire has similar psychometric properties in psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 2005, 52(Suppl 9):S402.
Mease P, Antoni C, Gladman DD, Taylor W: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl 2):ii49-ii54.
Gladman DD, Helliwell P, Mease PJ, et al.: Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24–35.
van der HeijdeD, Sharp J, Wassenberg S, et al.: Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005, 64(Suppl 2):ii61-ii64.
Mease P, van der Heidje D: Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006, 4:38–48.
Ory P, Gladman DD, Mease P: Psoriatic arthritis and imaging. Ann Rheum Dis 2005, 64(Suppl 2):ii55-ii57.
Baraliakos X, Braun J: Magnetic resonance imaging in spondyloarthropathies. Joint Bone Spine 2006, 73:1–3.
Gladman D, Mease P, Krueger G, et al.: Outcome measures in psoriatic arthritis. J Rheumatol 2005, 32:2262–2269. Summary of OMERACT 7 workshop on PsA domains and outcome measures.
Lebwohl M, Ting P, Koo J: Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005, 64(Suppl 64):ii83-ii86.
Mease P, Antoni C: Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005, 64(Suppl 2):ii78-ii82. Current review of biologics in PsA.
Nash P, Clegg DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005, 64(Suppl 2):ii74-ii77.
Winterfield L, Menter A, Gordon KB, Gottieb A: Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005, 64(Suppl 64):ii87-ii90.
Gordon KB, Ruderman EM: Synthesis and conclusion. In Psoriasis and Psoriatic Arthritis. Edited by Gordon KB, Ruderman EM. Berlin, Germany: Springer-Verlag Berlin Heidelberg; 2005:245–250.
Kaltwasser JP, Nash P, Gladman D, et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004, 50:1939–1950.
Fraser AD, van Kuijk AW, Westhovens R, et al.: A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005, 64:859–864.
Enbrel (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation; 2003.
Remicade (infliximab) prescribing information. Malvern, PA: Centocor Inc.; 2003.
HumiraTM (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories; 2003.
Mease P, Kivitz A, Burch F, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264–2272. 0Pivotal phase 3 study of etanercept in PsA.
Mease P, Ganguly L, Wanke E, et al.: How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004, 63(Suppl 1):391.
Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712–721.
Antoni C, Krueger GG, de VlamK, et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150–1157. Pivotal phase 3 study of infliximab in PsA.
Van der HeidjeD, Gladman D, Kavanaugh A, et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Arthritis Rheum 2005, 52(Suppl 9):S281.
Mease P, Kavanaugh A, Krueger G, et al.: Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 Trial. Arthritis Rheum 2004, 50(Suppl 9):S616.
Mease P, Gladman D, Ritchlin C: Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum 2005, 58:3279–3289. Pivotal phase 3 study of adalimumab in PsA.
Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65:423–432. Key summary review paper of therapies for AS.
Marra CA: Valuing health states and preferences of patients. Ann Rheum Dis 2005, 64(Suppl 3):36.
Guh D, Bansback N, Nosyk B, et al.: Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira). Ann Rheum Dis 2005, 64(Suppl 3):401.
Bansback N, Barkham N, Ara R, et al.: The economic implications of TNF-inhibitors in the treatment of psoriatic arthritis. Arthritis Rheum 2004, 50(Suppl 9):S509.
Hansen KE, Hildebrand JP, Genovese MC, et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1098–1102.
Haraoui B, Keystone EC, Thorne JC, et al.: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356–2359.
Bombardieri S, Tzioufas AG, McKenna F, et al.: Efficacy evaluation of adalimumab (Humira) in patients with single and multiple prior biologics in the ReAct trial. Arthritis Rheum 2004, 50(Suppl 9):S187.
Kraan MC, van Kuijk AW, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776–2784.
Krueger GG, Pap KA, Sough DB, et al.: A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002, 47:821–833.
Mease PJ, Gladman DD, Keystone EC: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 2006, 54:1638–1645.
Lebwohl M, Tyring SK, Hamilton TK, et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349:2004–2013.
Papp K, Mease P, Garovoy M, et al.: Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study. Presented at the International Psoriasis Symposium 2004. Toronto, Ontario; June 10/2-14, 2004.
Kremer JM, Westhovens R, Leon M, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907–1915.
Abrams JR, Lebwohl M, Guzzo C: CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243–1252.
McInnes IB, Gracie JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392–397.
Gibbs A, Gogarty M, Veale D, et al.: Efficacy of anakinra (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006, 65(Suppl 2):216–217.
Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005, 5:683–690.
Krueger C, Langley R, Leonardi C, Lebwohl M: Results of a phase II study of CNTO 1275 in the treatment of psoriasis. J Am Acad Dermatol 2006, 54:AB1. Accessible online at http://www.aad.org/aad/memberlogin.htm?return url=%2faad%2fPublicationsResources%2fjaad.htm.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mease, P. Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 8, 348–354 (2006). https://doi.org/10.1007/s11926-006-0064-9
Issue Date:
DOI: https://doi.org/10.1007/s11926-006-0064-9